Drugs That Disturb Sleep and Wakefulness

Principles and Practice of Sleep Medicine: Fifth Edition

Volumn , Issue , 2010, Pages 542-560

  Schweitzer, Paula K ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906845196     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6645-3.00046-3     Document Type: Chapter

References (226)

1. Saper CB, Scammell T, Lu J Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
2. Monti J, Jantos H The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 2008, 172:625-646.
3. Szabadi E Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006, 61:761-766.
4. Benca RM, Obermeyer WH, Thisted RA, Gillin JC Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 1992, 49:651-668.
5. Claghorn JL, Mathew RJ, Weinman ML, et al. Daytime sleepiness in depression. J Clin Psychiatry 1981, 42:342-343.
6. Newman AB, Enright PL, Manolio TA, et al. Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study. J Am Geriatr Soc 1997, 45:1-7.
7. Nebes RD, Pollock BG, Houck PR, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 2003, 37:99-108.
8. Maurer I, Volz H Cell-mediated side effects of psychopharmacological treatment. Arzneimittelforschung 2001, 51:785-792.
9. Mayers AG, Baldwin DS Antidepressants and their effect on sleep. Hum Psychopharmacol 2005, 20:533-559.
10. Wilson S, Argyropoulos S Antidepressants and sleep. A qualitative review of the literature. Drugs 2006, 65:927-947.
11. DeMartinis NA, Winokur A Effects of psychiatric medications on sleep and sleep disorders. CNS Neurol Disord Drug Targets 2007, 6:17-29.
12. Volz H-P, Sturm Y Antidepressant drugs and psychomotor performance. Neuropsychobiology 1995, 31:146-155.
13. Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010, 24:713-720.
14. Remick RA, Froese C, Keller FD Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 1989, 13:497-504.
15. Wyatt RJ, Fram DH, Kupfer DJ, et al. Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch Gen Psychiatry 1971, 24:145-155.
16. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology (Berl) 1992, 106:S56-S61.
17. Monti JM, Alterwain P, Monti D The effects of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 1990, 20:201-208.
18. Robinson DS, Amsterdam JD The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord 2008, 105:15-23.
19. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005, 143:415-426.
20. Kent JM SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000, 335:911-918.
21. Oberndorfer S, Saletu-Zyhlarz G, Saletu B Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 2000, 42:69-81.
22. Nicholson AN, Pascoe PA Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology 1988, 27:597-602.
23. Kerkhofs M, Rielaert C, de Maertelaer V, et al. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. Int Clin Psychopharmacol 1990, 5:253-260.
24. Schenck CH, Mahowald MW, Kim SW, et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992, 15:226-235.
25. Rottach K, Schaner B, Kirch M, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2009, 43:70-75.
26. Winkelman J, James L Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004, 27:317-321.
27. Sharpley AL, Williamson DJ, Attenburrow ME, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996, 126:50-54.
28. Staner L, Kerkhofs M, Detroux D, et al. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995, 18:470-477.
29. Kupfer DJ, Perel JM, Pollock BG, et al. Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 1991, 29:23-40.
30. van Bemmel AL, van den Hoofdakker RH, Beersma DG, et al. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl) 1993, 113:225-230.
31. Schmitt JAJ, Kruizinga MJ, Riedel WJ Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001, 15:173-179.
32. Wilson SJ, Bailey JE, Alford C, et al. Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. J Psychopharmacol 2000, 14:378-386.
33. Sultan A, Gaskell H, Derry S, Moore R Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomized trials. BMC Neurol 2008, 8:29.
34. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994, 14:99-106.
35. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005, 20:327-341.
36. Boyer P, Montgomery S, Lepola U Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008, 23:243-253.
37. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997, 58:348-350.
38. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull 1996, 32:637-646.
39. Chalon S, Pereira A, Lainey E, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005, 177:357-365.
40. Kluge M, Schussler P, Steiger A Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol 2007, 17:527-531.
41. Saletu B, Grunberger J, Anderer P, et al. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmacol 1992, 33:589-601.
42. Goldberg RJ Antidepressant use in the elderly: current status of nefazodone, venlafaxine and moclobemide. Drugs Aging 1997, 11:119-131.
43. Brown WD The effect of medication on sleep. Respir Care Clin 2006, 12:81-99.
44. Vogel G, Cohen J, Mullis D, et al. Nefazodone and REM sleep: how do antidepressant drugs decrease REM sleep?. Sleep 1998, 21:70-77.
45. Hindmarch I, Kerr J Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology (Berl) 1992, 106:S49-S55.
46. Frewer LJ, Lader M The effects of nefazodone, imipramine, and placebo, alone and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 1993, 8:13-20.
47. Nofzinger EA, Reynolds CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995, 152:274-276.
48. Preskorn SH Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995, 56(Suppl. 6):12-21.
49. Nofzinger EA, Fasiczka A, Berman S, et al. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000, 61:858-862.
50. Paul MA, Gray G, Kenny G, et al. The impact of bupropion on psychomotor performance. Aviat Space Environ Med 2002, 73:1094-1099.
51. Stahl S Stahl's essential psychopharmacology: neuroscientific basis and practical applications 2008, Cambridge University Press, New York. 3rd ed.
52. Winokur A, DeMartinis NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003, 64:1224-1229.
53. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008, 43:70-75.
54. Wingen M, Bothmer J, Langer S, Ramaekers JG Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005, 66:436-443.
55. Scates AC, Doraiswamy PM Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000, 34:1302-1312.
56. Kuenzel HE, Murck H, Held K, et al. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. Pharmacopsychiatry 2004, 37:193-195.
57. Siepmann M, Muck-Weymann M, Joraschky P, Kirch W The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2001, 157:202-207.
58. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006, 29:1573-1585.
59. Frazer A Pharmacology of antidepressants. J Clin Psychopharmacol 1997, 17(Suppl. 1):2S-18S.
60. Quera Salva M, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open label study. Int J Neuropsychopharmacol 2007, 10:691-696.
61. Obermeyer WH, Benca RM Effects of drugs on sleep. Neurol Clin 1996, 14:827-840.
62. Linnoila M, Rudorfer MV, Dubryoski KV, et al. Effects of one-week lithium treatment on skilled performance, information processing, and mood in healthy volunteers. J Clin Psychopharmacol 1986, 6:356-359.
63. 2 receptors?. Psychopharmacology (Berl) 1989, 98:139-140.
64. Hatcher S, Sims R, Thompson D The effects of chronic lithium treatment on psychomotor performance related to driving. Br J Psychiatry 1990, 157:275-278.
65. Krystal A, Goforth H, Roth T Effects of antipsychotic medications on sleep in schizophrenia. Int Clin Psychopharmacol 2008, 23:150-160.
66. Meltzer H, McGurk S The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
67. Fitton A, Heel RC Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990, 40:722-747.
68. Cohrs S Sleep disturbance in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008, 22:939-962.
69. 2C receptors in vivo. Biol Psychiatry 2000, 47:468-470.
70. Wetter TC, Lauer CJ, Gillich G, Pollmacher T The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiatr Res 1996, 30:411-419.
71. Vitiello B, Martin A, Hill J, et al. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 1997, 16:15-24.
72. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990, 16:477-499.
73. Dierks MR, Jordan JK, Sheehan AH Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother 2007, 41:1013-1017.
74. Seidel WF, Cohen SA, Wilson L, et al. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects. Psychopharmacology (Berl) 1985, 87:194-197.
75. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology 1995, 31:81-88.
76. Goa KL, Ward A Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986, 32:114-129.
77. Eison AS, Temple DL Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986, 80(Suppl. 3):61-68.
78. Newton RE, Casten GP, Alms DR, et al. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry 1982, 43:100-102.
79. Seidel WF, Cohen SA, Bliwise NG, et al. Buspirone: an anxiolytic without sedative effect. Psychopharmacology (Berl) 1985, 87:371-373.
80. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology 1995, 31:81-88.
81. Kennedy GM, Lhatoo SD CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008, 22:739-760.
82. Sammaritano M, Sherwin A Effect of anticonvulsants on sleep. Neurology 2000, 54:S16-S24.
83. Bazil CW Effects of antiepileptic drugs on sleep structure. Are all drugs equal?. CNS Drugs 2003, 17:719-728.
84. Johannessen Landmark C Antiepileptic drugs in non-epilepsy disorders. CNS Drugs 2008, 22:27-47.
85. Malow BA, Bowes RJ, Lix X Predictors of sleepiness in epilepsy patients. Sleep 1997, 20:1105-1110.
86. Salinsky MC, Oken BS, Binder LM Assessment of drowsiness in epilepsy patients receiving chronic antiepileptic drug therapy. Epilepsia 1996, 37:181-187.
87. Leppik IE Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994, 35(Suppl. 4):S29-S40.
88. Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996, 25:191-197.
89. Guay DR Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?. Am J Geriatr Pharmacother 2005, 3:274-287.
90. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56:1336-1344.
91. Sammaritano M, Sherwin A Effect of anticonvulsants on sleep. Neurology 2000, 54:S16-S24.
92. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002, 43:1493-1497.
93. Hindmarch I, Dawson J, Stanley N A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005, 28:187-193.
94. Cicolin A, Magliola U, Giordano A, et al. Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers. Epilepsia 2006, 47:82-85.
95. Salinsky M, Storzbach D, Oken B, Spencer D Topiramate effects on the EEG and alertness in healthy volunteers: a different profile of antiepileptic drug neurotoxicity. Epilepsy Behav 2007, 10:463-469.
96. Roeder-Wanner UU, Noachter S, Wolf P Response of polygraphic sleep to phenytoin treatment for epilepsy: a longitudinal study of immediate, short- and long-term effects. Acta Neurol Scand 1987, 76:157-167.
97. Palm L, Anderson H, Elmqvist D, et al. Daytime sleep tendency before and after discontinuation of antiepileptic drugs in preadolescent children with epilepsy. Epilepsia 1992, 33:687-691.
98. Bonanni E, Galli R, Maestri M, et al. Daytime sleepiness in epilepsy patients receiving topiramate monotherapy. Epilepsia 2004, 45:333-337.
99. Manni R, Ratti MT, Perucca E, et al. A multiparametric investigation of daytime sleepiness and psychomotor function in epileptic patients treated with phenobarbital and sodium valproate: a comparative controlled study. Electroencephalogr Clin Neurophysiol 1993, 86:322-328.
100. Trimble M Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987, 28(Suppl. 2):18-22.
101. Brunbech L, Sabers A Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. Drugs 2002, 62:593-604.
102. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999, 52:321-327.
103. van Hilten B, Hoff JI, Middelkoop MA, et al. Sleep disruption in Parkinson's disease. Arch Neurol 1994, 51:922-928.
104. Rye D, Bliwise D Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. Movement disorders: neurologic principles and practice 1977, 687-713. McGraw-Hill, New York. R.L. Watts, W.C. Joller (Eds.).
105. Gagnon JF, Bédard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002, 59:585-589.
106. Monaca C, Duhamel A, Jacquesson J, et al. Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. Sleep Med 2006, 7:448-453.
107. Kaakkola S Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000, 59:1233-1250.
108. Chrisp P, Mammen GJ, Sorkin EM Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991, 1:228-248.
109. Chisholm-Burns M, Chisholm M, Schwinghammer T, et al. Pharmacotherapy principles & practice 2008, McGraw-Hill Medical, New York.
110. Kvernmo T, Houben J, Syite I Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem 2008, 8:1049-1067.
111. Etminan M, Samii A, Takkouche B, et al. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf 2001, 24:863-868.
112. Chaudhuri KR, Pal S, Brefel-Courbon C "Sleep attacks" or "unintended sleep episodes" occur with dopamine agonists: is this a class effect?. Drug Saf 2002, 25:473-483.
113. Happe S, Berger K The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease-a prospective study. J Neurol 2001, 248:1062-1067.
114. Razmy A, Lang AE, Chapiro CM Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004, 61:97-102.
115. Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 2003, 4:275-280.
116. Shpirer I, Miniovitz A, Klein C, et al. Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. Mov Disord 2006, 21:1432-1438.
117. Suzuki K, Miyamoto T, Miyamoto M, et al. Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. J Neurol Sci 2008, 271:47-52.
118. Kaynak D, Kiziltan G, Kaynak H, et al. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 2005, 12:199-207.
119. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. Brain 1992, 115:1701-1725.
120. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000, 41:181-189.
121. Hamidovic A, Kang UJ, de Wit H Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 2008, 28:45-51.
122. Kimberg DY, D'Esposito M Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 2003, 41:1020-1027.
123. Brusa L, Tiraboschi P, Koch G, et al. Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transm 2005, 112:231-237.
124. Baker WL, White CM, Coleman CI Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Ann Fam Med 2008, 6:253-262.
125. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002, 252:185-194.
126. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000, 41:181-189.
127. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006, 67:1040-1046.
128. Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology 2002, 58:460-462.
129. McAinsh J, Cruickshank JM Beta-blockers and central nervous system side effects. Pharmacol Ther 1990, 46:163-197.
130. Yamada Y, Shibuya F, Hamada J, et al. Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. J Pharmacokinet Biopharm 1995, 23:131-145.
131. Dahlöf C, Dimenäs E Side effects of beta-blocker treatments as related to the central nervous system. Am J Med Sci 1990, 299:236-244.
132. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999, 55:111-115.
133. Pearce CJ, Wallin JD Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med 1994, 61:59-69.
134. Yilmaz M, Erdem A, Yalta K, et al. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Adv Ther 2008, 25:871-883.
135. Betts TA, Alford C Beta-blockers and sleep: a controlled trial. Eur J Clin Pharmacol 1985, 28(Suppl.):65-68.
136. Paykel ES, Fleminger R, Watson JP Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982, 2:14-39.
137. Kostis JB, Rosen RC, Holzer BC, et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990, 102:163-170.
138. Kanno O, Clarenbach P Effects of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalogr Clin Neurophysiol 1985, 60:478-484.
139. Carskadon MA, Cavallo A, Rosekind MR Sleepiness and nap sleep following a morning dose of clonidine. Sleep 1989, 12:338-344.
140. Croog SH, Levine S, Testa MA, et al. The effects of antihyper-tensive therapy on the quality of life. N Engl J Med 1986, 314:1657-1664.
141. Keech AC, Armitage JM, Wallendszus KR, et al. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Br J Clin Pharmacol 1996, 42:483-490.
142. Ehrenberg BL, Lamon-Fava S, Corbett KE, et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep 1999, 22:117-121.
143. Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992, 15:426-432.
144. Vgontzas A, Kales A, Bixler E, et al. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991, 50:730-737.
145. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
146. Etminan M, Gill S, Samii A The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003, 23:726-730.
147. Raskind M, Peskind E, Hoff D, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007, 15:928-934.
148. Taylor F, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008, 63:629-632.
149. Monti J Minireview: disturbances of sleep and wakefulness associated with the use of antihypertensive agents. Life Sci 1987, 41:1979-1988.
150. Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234-242.
151. Cicolin A, Mangiardi L, Mutani R, et al. Angiotensin-converting enzyme inhibitors and obstructive sleep apnea. Mayo Clin Proc 2006, 81:53-55.
152. Okamura N, Yanai K, Higuchi M, et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000, 129:115-123.
153. 1 receptors in human brain. Life Sci 2002, 72:409-414.
154. Meltzer E Performance effects of antihistamines. J Allergy Clin Immunol 1990, 86:613-619.
155. Shamsi Z, Hindmarch I Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Human Psychopharmacol 2000, 15:S3-S30.
156. Schweitzer PK, Muehlbach MJ, Walsh JK Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994, 94:716-724.
157. 1 antihistamines. J Clin Psychopharmacol 2002, 22:511-515.
158. 11C-doxepin positron emission tomography. J Clin Pharmacol 2004, 44:890-900.
159. Hindmarch I Psychometric aspects of antihistamines. Allergy 1990, 50:48-54.
160. Verster JC, Volkerts ER Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004, 92:294-303.
161. Bender B, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003, 111:770-776.
162. Hindmarch I CNS effects of antihistamines: is there a third generation of non-sedative drugs?. Clin Exp Allergy Rev 2002, 2:26-31.
163. Raemaekers J, Vermeeren A All antihistamines cross blood-brain barrier. BMJ 2000, 321:572.
164. 2-receptor antagonists and benzodiazepine sedation. A double-blind placebo-controlled investigation of the effects of cimetidine and ranitidine on recovery after intravenous midazolam. Anaesthesia 1993, 48:286-292.
165. 2-receptor antagonists on subjective and objective assessments of sleep. Aliment Pharmacol Ther 1994, 8:203-207.
166. Schentag JJ Cimetidine-associated mental confusion: further studies in 36 severely ill patients. Ther Drug Monit 1980, 78:791-795.
167. 2-receptor antagonists and benzodiazepine sedation. Anaesthesia 1993, 48:286-292.
168. Roehrs T, Roth T Sleep and pain: interaction of two vital functions. Semin Neurol 2005, 25:106-116.
169. Schug S, Garrett W, Gillespie G Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 2003, 17:91-110.
170. Zin C, Nissen L, Smith M, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008, 22:417-422.
171. Gutstein H, Akil H Opioid analgesics. Goodman and Gilman's the pharmacological basis of therapeutics 2005, 547-590. McGraw-Hill, New York. 11th ed. J. Hardman, L. Limbird, A. Gilman (Eds.).
172. Wilson L, Dorosz L Possible role of the opioid peptides in sleep. Med Hypotheses 1984, 14:269-280.
173. Inturrisi C Clinical pharmacology of opioids for pain. Clin J Pain 2002, 18:S3-S13.
174. Clemons M, Regnard C, Appleton T Alertness, cognition and morphine in patients with advanced cancer. Cancer Treat Rev 1996, 122:451-468.
175. Zgierska A, Brown R, Zuelsdorff M, et al. Sleep and daytime sleepiness problems among patients with chronic noncancerous pain receiving long-term opioid therapy: a cross-sectional study. J Opioid Manag 2007, 3:317-327.
176. Nikolaus T, Zeyfang A Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging 2004, 21:19-41.
177. Dimsdale J, Norman D, DeJardin D, Wallace M The effects of opioids on sleep architecture. J Clin Sleep Med 2007, 3:33-36.
178. Walder B, Tramer M, Blois R The effects of two single doses of tramadol on sleep: a randomized, cross-over trial in healthy volunteers. Eur J Anaesthesiol 2001, 18:36-42.
179. Cronin A, Keifer J, Davies M, et al. Postoperative sleep disturbance: influences of opioids and pain in humans. Sleep 2001, 24:39-44.
180. Caldwell J, Rapoport R, Davis J, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized placebo- controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002, 23:278-291.
181. Sjogran P Psychomotor and cognitive functioning in cancer patients. Acta Anaesthesiol Scand 1997, 41:159-161.
182. Brown R, Zuelsdorff M, Fleming M Adverse effects and cognitive function among primary care patients taking opioids for chronic nonmalignant pain. J Opioid Manag 2006, 2:137-145.
183. Robinson R, Zwillich C, Bixler E, et al. Effects of oral narcotics on sleep-disordered breathing in healthy adults. Chest 1987, 91:197-203.
184. Shook JE, Watkins W, Camporesi E Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. Am Rev Respir Dis 1990, 142:895-909.
185. Robinson R, Zwillich C, Bixler E, et al. Effects of oral narcotics on sleep-disordered breathing in healthy adults. Chest 1987, 91:197-203.
186. Wang D, Teichtahl H Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev 2007, 11:35-46.
187. Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest 2005, 128:1348-1356.
188. Farney R, Walker J, Cloward T, Rhondeau S Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003, 123:632-639.
189. Catley D, Thornton C, Jordan C, et al. Pronounced, episodic oxygen desaturation in the postoperative period: its association with ventilatory pattern and analgesic regimen. Anesthesiology 1985, 63:20-28.
190. Dodick D, Martin V Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004, 24:417-424.
191. Murphy P, Badia P, Myers B, et al. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav 1994, 55:1063-1066.
192. Datta S, MacLean R Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. Neurosci Biobehav Rev 2007, 31:775-824.
193. Nikolaus T, Zeyfang A Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging 2004, 21:19-41.
194. Gengo F Effects of ibuprofen on sleep quality as measured using polysomnography and subjective measures in healthy adults. Clin Ther 2006, 28:1820-1826.
195. Horne J, Percival J, Traynor J Aspirin and human sleep. Electroencephalogr Clin Neurophysiol 1980, 49:409-413.
196. Lavie P, Hahir M, Lorder M, Scharf Y Nonsteroidal anti-inflammatory drug therapy in rheumatoid arthritis. Lack of association between clinical improvement and effect on sleep. Arthritis Rheum 1991, 34:655-659.
197. Schug S, Garrett W, Gillespie G Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 2003, 17:91-110.
198. Searle JP, Compton MR Side-effects of corticosteroid agents. Med J Aust 1986, 144:139-142.
199. Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110-2112.
200. Lozada F, Silverman S, Migliorati C Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. J Am Dent Assoc 1984, 109:269-270.
201. Harris JC, Carel CA, Rosenberg LA, et al. Intermittent high dose corticosteroid treatment in childhood cancer: behavioral and emotional consequences. J Am Acad Child Adolesc Psychiatry 1988, 27:720-725.
202. Bailey WC, Richards JM, Manzella BA, et al. Characteristics and correlates of asthma in a university clinic population. Chest 1990, 98:821-828.
203. Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior: preliminary findings. Arch Gen Psychiatry 1990, 47:963-968.
204. Born J, Zwick A, Roth G, et al. Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal sleep in humans. Acta Endocrinol (Copenh) 1987, 116:129-137.
205. Rosenthal L, Folkerts M, Helmus T, et al. Administration of dexamethasone and its effects on sleep and daytime alertness. Sleep Res 1995, 24:58.
206. Wolkowitz OM, Reus VI, Weingartner H, et al. Cognitive effects of corticosteroids. Am J Psychiatry 1990, 147:1297-1303.
207. McLaurin E, Holliday S, Williams P, Brey R Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005, 64:297-303.
208. Lake CR, Rosenberg DB, Gallant S, et al. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990, 47:675-685.
209. Bertrand B, Jamart J, Arendt C Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 1996, 34:91-96.
210. Cohen-Zion M, Ancoli-Israel S Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004, 8:379-402.
211. Sobanski E, Schredl M, Kettler N, Alm B Sleep in adults with attention deficit hyperactivity disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 2008, 31:375-381.
212. Boonstra AM, Kooij JJS, Oosterlaan J, et al. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep 2007, 30:433-442.
213. Kumar R Approved and investigational use of modafinil: an evidence-based review. Drugs 2008, 68:1803-1839.
214. Scott PH, Tabachnik E, MacLeod S, et al. Sustained release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr 1981, 99:476-479.
215. Hendeles L, Massanari M, Weinberger M Update on the pharmacodynamics and pharmacokinetics of theophylline. Chest 1985, 88(Suppl.):103S-111S.
216. Janson C, Gislason T, Boman G, et al. Sleep disturbances in patients with asthma. Respir Med 1990, 84:37-42.
217. Kraft M, Wenzel SE, Bettinger CM, et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997, 111:1249-1254.
218. Kaplan J, Fredrickson PA, Renaux SA, et al. Theophylline effect on sleep in normal subjects. Chest 1993, 103:193-195.
219. Roehrs T, Merlotti L, Halpin D, et al. Effects of theophylline on nocturnal sleep and daytime sleepiness/alertness. Chest 1995, 108:382-387.
220. Rhind GB, Connaughton JJ, McFie J, et al. Sustained release choline theophyllinate in nocturnal asthma. BMJ 1985, 291:1605-1607.
221. 2 in children with cystic fibrosis. Am Rev Respir Dis 1991, 144:1245-1249.
222. Saletu B, Oberndorfer S, Anderer P, et al. Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology 1999, 39:151-159.
223. Mulloy E, McNicholas WT Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993, 148:1030-1036.
224. Rachelefsky GS, Wo J, Adelson J, et al. Behavior abnormalities and poor school performance due to oral theophylline use. Pediatrics 1986, 78:1133-1138.
225. Stein MA, Krasowski M, Leventhal BL, et al. Behavioral and cognitive effects of methylxanthines: a meta-analysis of theophylline and caffeine. Arch Pediatr Adolesc Med 1996, 150:284-288.
226. Lindgren S, Lokshin B, Stromquist A, et al. Does asthma or treatment with theophylline limit children's academic performance?. N Engl J Med 1992, 327:926-930.